nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP3A7—Paclitaxel—ovarian cancer	0.0773	0.128	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0773	0.128	CbGbCtD
Ondansetron—CYP3A5—Paclitaxel—ovarian cancer	0.058	0.096	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0559	0.0925	CbGbCtD
Ondansetron—CYP3A7—Docetaxel—ovarian cancer	0.0559	0.0925	CbGbCtD
Ondansetron—CYP2D6—Vinorelbine—ovarian cancer	0.0506	0.0838	CbGbCtD
Ondansetron—CYP3A4—Topotecan—ovarian cancer	0.0457	0.0756	CbGbCtD
Ondansetron—CYP3A5—Docetaxel—ovarian cancer	0.0419	0.0694	CbGbCtD
Ondansetron—CYP2C9—Paclitaxel—ovarian cancer	0.0389	0.0644	CbGbCtD
Ondansetron—CYP3A4—Vinorelbine—ovarian cancer	0.0322	0.0533	CbGbCtD
Ondansetron—CYP3A4—Paclitaxel—ovarian cancer	0.0226	0.0374	CbGbCtD
Ondansetron—CYP2D6—Doxorubicin—ovarian cancer	0.0192	0.0317	CbGbCtD
Ondansetron—CYP3A4—Docetaxel—ovarian cancer	0.0164	0.0271	CbGbCtD
Ondansetron—CYP3A4—Doxorubicin—ovarian cancer	0.0122	0.0202	CbGbCtD
Ondansetron—SLC47A2—vagina—ovarian cancer	0.00167	0.0958	CbGeAlD
Ondansetron—SLC47A1—myometrium—ovarian cancer	0.00111	0.0636	CbGeAlD
Ondansetron—SLC47A1—uterine cervix—ovarian cancer	0.000862	0.0495	CbGeAlD
Ondansetron—SLC47A1—decidua—ovarian cancer	0.000821	0.0472	CbGeAlD
Ondansetron—SLC47A1—endometrium—ovarian cancer	0.00078	0.0448	CbGeAlD
Ondansetron—SLC47A1—gonad—ovarian cancer	0.000723	0.0415	CbGeAlD
Ondansetron—SLC47A1—uterus—ovarian cancer	0.000718	0.0413	CbGeAlD
Ondansetron—KCNH2—myometrium—ovarian cancer	0.00068	0.039	CbGeAlD
Ondansetron—SLC47A1—female reproductive system—ovarian cancer	0.000646	0.0371	CbGeAlD
Ondansetron—SLC47A1—female gonad—ovarian cancer	0.000588	0.0337	CbGeAlD
Ondansetron—SLC47A1—vagina—ovarian cancer	0.000584	0.0335	CbGeAlD
Ondansetron—HTR1B—female reproductive system—ovarian cancer	0.000552	0.0317	CbGeAlD
Ondansetron—Pruritus—Melphalan—ovarian cancer	0.000549	0.00147	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Epirubicin—ovarian cancer	0.000548	0.00147	CcSEcCtD
Ondansetron—Haemoglobin—Docetaxel—ovarian cancer	0.000547	0.00146	CcSEcCtD
Ondansetron—Hepatic failure—Doxorubicin—ovarian cancer	0.000546	0.00146	CcSEcCtD
Ondansetron—Haemorrhage—Docetaxel—ovarian cancer	0.000544	0.00146	CcSEcCtD
Ondansetron—Diarrhoea—Topotecan—ovarian cancer	0.000542	0.00145	CcSEcCtD
Ondansetron—Urticaria—Vinorelbine—ovarian cancer	0.000538	0.00144	CcSEcCtD
Ondansetron—Abdominal pain—Vinorelbine—ovarian cancer	0.000536	0.00144	CcSEcCtD
Ondansetron—Body temperature increased—Vinorelbine—ovarian cancer	0.000536	0.00144	CcSEcCtD
Ondansetron—Diarrhoea—Melphalan—ovarian cancer	0.000531	0.00142	CcSEcCtD
Ondansetron—KCNH2—uterine cervix—ovarian cancer	0.000529	0.0304	CbGeAlD
Ondansetron—Vision blurred—Paclitaxel—ovarian cancer	0.000526	0.00141	CcSEcCtD
Ondansetron—Visual impairment—Docetaxel—ovarian cancer	0.000524	0.0014	CcSEcCtD
Ondansetron—Dizziness—Topotecan—ovarian cancer	0.000524	0.0014	CcSEcCtD
Ondansetron—Tremor—Paclitaxel—ovarian cancer	0.000523	0.0014	CcSEcCtD
Ondansetron—SLC47A1—testis—ovarian cancer	0.000521	0.0299	CbGeAlD
Ondansetron—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000518	0.00139	CcSEcCtD
Ondansetron—Erythema multiforme—Docetaxel—ovarian cancer	0.000514	0.00138	CcSEcCtD
Ondansetron—Agitation—Paclitaxel—ovarian cancer	0.000513	0.00138	CcSEcCtD
Ondansetron—Angioedema—Paclitaxel—ovarian cancer	0.00051	0.00137	CcSEcCtD
Ondansetron—Eye disorder—Docetaxel—ovarian cancer	0.000508	0.00136	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Doxorubicin—ovarian cancer	0.000507	0.00136	CcSEcCtD
Ondansetron—Cardiac disorder—Docetaxel—ovarian cancer	0.000505	0.00135	CcSEcCtD
Ondansetron—Flushing—Docetaxel—ovarian cancer	0.000505	0.00135	CcSEcCtD
Ondansetron—Vomiting—Topotecan—ovarian cancer	0.000504	0.00135	CcSEcCtD
Ondansetron—Malaise—Paclitaxel—ovarian cancer	0.000504	0.00135	CcSEcCtD
Ondansetron—Syncope—Paclitaxel—ovarian cancer	0.000501	0.00134	CcSEcCtD
Ondansetron—Rash—Topotecan—ovarian cancer	0.000499	0.00134	CcSEcCtD
Ondansetron—Hypersensitivity—Vinorelbine—ovarian cancer	0.000499	0.00134	CcSEcCtD
Ondansetron—Dermatitis—Topotecan—ovarian cancer	0.000499	0.00134	CcSEcCtD
Ondansetron—Headache—Topotecan—ovarian cancer	0.000496	0.00133	CcSEcCtD
Ondansetron—Palpitations—Paclitaxel—ovarian cancer	0.000494	0.00132	CcSEcCtD
Ondansetron—Angiopathy—Docetaxel—ovarian cancer	0.000493	0.00132	CcSEcCtD
Ondansetron—Vomiting—Melphalan—ovarian cancer	0.000493	0.00132	CcSEcCtD
Ondansetron—Immune system disorder—Docetaxel—ovarian cancer	0.000491	0.00132	CcSEcCtD
Ondansetron—Loss of consciousness—Paclitaxel—ovarian cancer	0.000491	0.00132	CcSEcCtD
Ondansetron—Mediastinal disorder—Docetaxel—ovarian cancer	0.00049	0.00131	CcSEcCtD
Ondansetron—Liver function test abnormal—Epirubicin—ovarian cancer	0.00049	0.00131	CcSEcCtD
Ondansetron—Rash—Melphalan—ovarian cancer	0.000489	0.00131	CcSEcCtD
Ondansetron—Dermatitis—Melphalan—ovarian cancer	0.000489	0.00131	CcSEcCtD
Ondansetron—Chills—Docetaxel—ovarian cancer	0.000488	0.00131	CcSEcCtD
Ondansetron—Cough—Paclitaxel—ovarian cancer	0.000487	0.00131	CcSEcCtD
Ondansetron—OPRM1—testis—ovarian cancer	0.000486	0.0279	CbGeAlD
Ondansetron—Asthenia—Vinorelbine—ovarian cancer	0.000486	0.0013	CcSEcCtD
Ondansetron—Arrhythmia—Docetaxel—ovarian cancer	0.000486	0.0013	CcSEcCtD
Ondansetron—Convulsion—Paclitaxel—ovarian cancer	0.000484	0.0013	CcSEcCtD
Ondansetron—Hypokalaemia—Epirubicin—ovarian cancer	0.000483	0.00129	CcSEcCtD
Ondansetron—Pruritus—Vinorelbine—ovarian cancer	0.000479	0.00128	CcSEcCtD
Ondansetron—KCNH2—endometrium—ovarian cancer	0.000478	0.0275	CbGeAlD
Ondansetron—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000477	0.00128	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000477	0.00128	CcSEcCtD
Ondansetron—Chest pain—Paclitaxel—ovarian cancer	0.000475	0.00127	CcSEcCtD
Ondansetron—Anxiety—Paclitaxel—ovarian cancer	0.000474	0.00127	CcSEcCtD
Ondansetron—Erythema—Docetaxel—ovarian cancer	0.000473	0.00127	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000472	0.00127	CcSEcCtD
Ondansetron—Discomfort—Paclitaxel—ovarian cancer	0.00047	0.00126	CcSEcCtD
Ondansetron—Dry mouth—Paclitaxel—ovarian cancer	0.000465	0.00125	CcSEcCtD
Ondansetron—Diarrhoea—Vinorelbine—ovarian cancer	0.000464	0.00124	CcSEcCtD
Ondansetron—Asthma—Epirubicin—ovarian cancer	0.000458	0.00123	CcSEcCtD
Ondansetron—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000456	0.00122	CcSEcCtD
Ondansetron—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000453	0.00121	CcSEcCtD
Ondansetron—Shock—Paclitaxel—ovarian cancer	0.000448	0.0012	CcSEcCtD
Ondansetron—Dizziness—Vinorelbine—ovarian cancer	0.000448	0.0012	CcSEcCtD
Ondansetron—Nervous system disorder—Paclitaxel—ovarian cancer	0.000447	0.0012	CcSEcCtD
Ondansetron—Hypokalaemia—Doxorubicin—ovarian cancer	0.000446	0.0012	CcSEcCtD
Ondansetron—Angina pectoris—Epirubicin—ovarian cancer	0.000446	0.0012	CcSEcCtD
Ondansetron—Tachycardia—Paclitaxel—ovarian cancer	0.000445	0.00119	CcSEcCtD
Ondansetron—Skin disorder—Paclitaxel—ovarian cancer	0.000443	0.00119	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000442	0.00118	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.000442	0.00118	CcSEcCtD
Ondansetron—KCNH2—uterus—ovarian cancer	0.000441	0.0253	CbGeAlD
Ondansetron—CYP3A5—uterine cervix—ovarian cancer	0.000437	0.0251	CbGeAlD
Ondansetron—Vomiting—Vinorelbine—ovarian cancer	0.000431	0.00115	CcSEcCtD
Ondansetron—Dysuria—Epirubicin—ovarian cancer	0.000429	0.00115	CcSEcCtD
Ondansetron—Rash—Vinorelbine—ovarian cancer	0.000427	0.00115	CcSEcCtD
Ondansetron—Dermatitis—Vinorelbine—ovarian cancer	0.000427	0.00114	CcSEcCtD
Ondansetron—Hypotension—Paclitaxel—ovarian cancer	0.000426	0.00114	CcSEcCtD
Ondansetron—Headache—Vinorelbine—ovarian cancer	0.000425	0.00114	CcSEcCtD
Ondansetron—Syncope—Docetaxel—ovarian cancer	0.000425	0.00114	CcSEcCtD
Ondansetron—Asthma—Doxorubicin—ovarian cancer	0.000424	0.00114	CcSEcCtD
Ondansetron—Palpitations—Docetaxel—ovarian cancer	0.000418	0.00112	CcSEcCtD
Ondansetron—Loss of consciousness—Docetaxel—ovarian cancer	0.000416	0.00111	CcSEcCtD
Ondansetron—Cough—Docetaxel—ovarian cancer	0.000413	0.00111	CcSEcCtD
Ondansetron—Angina pectoris—Doxorubicin—ovarian cancer	0.000413	0.00111	CcSEcCtD
Ondansetron—Convulsion—Docetaxel—ovarian cancer	0.00041	0.0011	CcSEcCtD
Ondansetron—Paraesthesia—Paclitaxel—ovarian cancer	0.000409	0.0011	CcSEcCtD
Ondansetron—Drowsiness—Epirubicin—ovarian cancer	0.000409	0.00109	CcSEcCtD
Ondansetron—Dyspnoea—Paclitaxel—ovarian cancer	0.000406	0.00109	CcSEcCtD
Ondansetron—Somnolence—Paclitaxel—ovarian cancer	0.000405	0.00109	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000405	0.00109	CcSEcCtD
Ondansetron—Chest pain—Docetaxel—ovarian cancer	0.000403	0.00108	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.0004	0.00107	CcSEcCtD
Ondansetron—Urinary tract infection—Epirubicin—ovarian cancer	0.000397	0.00106	CcSEcCtD
Ondansetron—Dysuria—Doxorubicin—ovarian cancer	0.000396	0.00106	CcSEcCtD
Ondansetron—KCNH2—female reproductive system—ovarian cancer	0.000396	0.0228	CbGeAlD
Ondansetron—Dry mouth—Docetaxel—ovarian cancer	0.000394	0.00106	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000394	0.00105	CcSEcCtD
Ondansetron—Fatigue—Paclitaxel—ovarian cancer	0.000393	0.00105	CcSEcCtD
Ondansetron—Pain—Paclitaxel—ovarian cancer	0.00039	0.00104	CcSEcCtD
Ondansetron—Constipation—Paclitaxel—ovarian cancer	0.00039	0.00104	CcSEcCtD
Ondansetron—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000386	0.00104	CcSEcCtD
Ondansetron—Anaphylactic shock—Docetaxel—ovarian cancer	0.000386	0.00104	CcSEcCtD
Ondansetron—Shock—Docetaxel—ovarian cancer	0.00038	0.00102	CcSEcCtD
Ondansetron—Nervous system disorder—Docetaxel—ovarian cancer	0.000379	0.00102	CcSEcCtD
Ondansetron—Drowsiness—Doxorubicin—ovarian cancer	0.000378	0.00101	CcSEcCtD
Ondansetron—SLC47A1—lymph node—ovarian cancer	0.000378	0.0217	CbGeAlD
Ondansetron—Tachycardia—Docetaxel—ovarian cancer	0.000377	0.00101	CcSEcCtD
Ondansetron—Feeling abnormal—Paclitaxel—ovarian cancer	0.000376	0.00101	CcSEcCtD
Ondansetron—Skin disorder—Docetaxel—ovarian cancer	0.000375	0.00101	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000375	0.001	CcSEcCtD
Ondansetron—KCNH2—bone marrow—ovarian cancer	0.000374	0.0215	CbGeAlD
Ondansetron—Bradycardia—Epirubicin—ovarian cancer	0.000373	0.001	CcSEcCtD
Ondansetron—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000373	0.000999	CcSEcCtD
Ondansetron—Haemoglobin—Epirubicin—ovarian cancer	0.000369	0.000988	CcSEcCtD
Ondansetron—Urinary tract infection—Doxorubicin—ovarian cancer	0.000367	0.000985	CcSEcCtD
Ondansetron—Haemorrhage—Epirubicin—ovarian cancer	0.000367	0.000983	CcSEcCtD
Ondansetron—Urticaria—Paclitaxel—ovarian cancer	0.000362	0.00097	CcSEcCtD
Ondansetron—Hypotension—Docetaxel—ovarian cancer	0.000361	0.000967	CcSEcCtD
Ondansetron—KCNH2—female gonad—ovarian cancer	0.000361	0.0207	CbGeAlD
Ondansetron—Abdominal pain—Paclitaxel—ovarian cancer	0.00036	0.000966	CcSEcCtD
Ondansetron—Body temperature increased—Paclitaxel—ovarian cancer	0.00036	0.000966	CcSEcCtD
Ondansetron—KCNH2—vagina—ovarian cancer	0.000358	0.0206	CbGeAlD
Ondansetron—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000358	0.000958	CcSEcCtD
Ondansetron—Visual impairment—Epirubicin—ovarian cancer	0.000353	0.000947	CcSEcCtD
Ondansetron—Paraesthesia—Docetaxel—ovarian cancer	0.000347	0.00093	CcSEcCtD
Ondansetron—Erythema multiforme—Epirubicin—ovarian cancer	0.000347	0.000929	CcSEcCtD
Ondansetron—Bradycardia—Doxorubicin—ovarian cancer	0.000346	0.000926	CcSEcCtD
Ondansetron—Dyspnoea—Docetaxel—ovarian cancer	0.000344	0.000923	CcSEcCtD
Ondansetron—Somnolence—Docetaxel—ovarian cancer	0.000343	0.00092	CcSEcCtD
Ondansetron—Eye disorder—Epirubicin—ovarian cancer	0.000343	0.000919	CcSEcCtD
Ondansetron—Haemoglobin—Doxorubicin—ovarian cancer	0.000341	0.000914	CcSEcCtD
Ondansetron—Flushing—Epirubicin—ovarian cancer	0.00034	0.000912	CcSEcCtD
Ondansetron—Cardiac disorder—Epirubicin—ovarian cancer	0.00034	0.000912	CcSEcCtD
Ondansetron—Haemorrhage—Doxorubicin—ovarian cancer	0.000339	0.000909	CcSEcCtD
Ondansetron—Hypersensitivity—Paclitaxel—ovarian cancer	0.000336	0.0009	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000334	0.000894	CcSEcCtD
Ondansetron—Fatigue—Docetaxel—ovarian cancer	0.000333	0.000893	CcSEcCtD
Ondansetron—Angiopathy—Epirubicin—ovarian cancer	0.000333	0.000892	CcSEcCtD
Ondansetron—Immune system disorder—Epirubicin—ovarian cancer	0.000331	0.000888	CcSEcCtD
Ondansetron—Mediastinal disorder—Epirubicin—ovarian cancer	0.000331	0.000886	CcSEcCtD
Ondansetron—Constipation—Docetaxel—ovarian cancer	0.00033	0.000885	CcSEcCtD
Ondansetron—Pain—Docetaxel—ovarian cancer	0.00033	0.000885	CcSEcCtD
Ondansetron—Chills—Epirubicin—ovarian cancer	0.000329	0.000882	CcSEcCtD
Ondansetron—Arrhythmia—Epirubicin—ovarian cancer	0.000328	0.000878	CcSEcCtD
Ondansetron—Visual impairment—Doxorubicin—ovarian cancer	0.000327	0.000876	CcSEcCtD
Ondansetron—Asthenia—Paclitaxel—ovarian cancer	0.000327	0.000876	CcSEcCtD
Ondansetron—Pruritus—Paclitaxel—ovarian cancer	0.000322	0.000864	CcSEcCtD
Ondansetron—CYP2C9—female reproductive system—ovarian cancer	0.000322	0.0185	CbGeAlD
Ondansetron—Erythema multiforme—Doxorubicin—ovarian cancer	0.000321	0.00086	CcSEcCtD
Ondansetron—KCNH2—testis—ovarian cancer	0.00032	0.0184	CbGeAlD
Ondansetron—Erythema—Epirubicin—ovarian cancer	0.000319	0.000856	CcSEcCtD
Ondansetron—Feeling abnormal—Docetaxel—ovarian cancer	0.000318	0.000853	CcSEcCtD
Ondansetron—Eye disorder—Doxorubicin—ovarian cancer	0.000317	0.00085	CcSEcCtD
Ondansetron—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000316	0.000847	CcSEcCtD
Ondansetron—Cardiac disorder—Doxorubicin—ovarian cancer	0.000315	0.000844	CcSEcCtD
Ondansetron—Flushing—Doxorubicin—ovarian cancer	0.000315	0.000844	CcSEcCtD
Ondansetron—Flatulence—Epirubicin—ovarian cancer	0.000315	0.000843	CcSEcCtD
Ondansetron—Diarrhoea—Paclitaxel—ovarian cancer	0.000312	0.000836	CcSEcCtD
Ondansetron—Angiopathy—Doxorubicin—ovarian cancer	0.000308	0.000825	CcSEcCtD
Ondansetron—Immune system disorder—Doxorubicin—ovarian cancer	0.000307	0.000821	CcSEcCtD
Ondansetron—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000306	0.00082	CcSEcCtD
Ondansetron—Abdominal pain—Docetaxel—ovarian cancer	0.000305	0.000818	CcSEcCtD
Ondansetron—Body temperature increased—Docetaxel—ovarian cancer	0.000305	0.000818	CcSEcCtD
Ondansetron—CYP2E1—female reproductive system—ovarian cancer	0.000305	0.0175	CbGeAlD
Ondansetron—Chills—Doxorubicin—ovarian cancer	0.000305	0.000816	CcSEcCtD
Ondansetron—Arrhythmia—Doxorubicin—ovarian cancer	0.000303	0.000812	CcSEcCtD
Ondansetron—Dizziness—Paclitaxel—ovarian cancer	0.000301	0.000808	CcSEcCtD
Ondansetron—Vision blurred—Epirubicin—ovarian cancer	0.000301	0.000806	CcSEcCtD
Ondansetron—CYP3A5—female gonad—ovarian cancer	0.000298	0.0171	CbGeAlD
Ondansetron—Ill-defined disorder—Epirubicin—ovarian cancer	0.000296	0.000794	CcSEcCtD
Ondansetron—CYP3A5—vagina—ovarian cancer	0.000296	0.017	CbGeAlD
Ondansetron—Erythema—Doxorubicin—ovarian cancer	0.000295	0.000792	CcSEcCtD
Ondansetron—Agitation—Epirubicin—ovarian cancer	0.000293	0.000786	CcSEcCtD
Ondansetron—Flatulence—Doxorubicin—ovarian cancer	0.000291	0.00078	CcSEcCtD
Ondansetron—Vomiting—Paclitaxel—ovarian cancer	0.00029	0.000777	CcSEcCtD
Ondansetron—Malaise—Epirubicin—ovarian cancer	0.000288	0.000772	CcSEcCtD
Ondansetron—Rash—Paclitaxel—ovarian cancer	0.000287	0.00077	CcSEcCtD
Ondansetron—Dermatitis—Paclitaxel—ovarian cancer	0.000287	0.000769	CcSEcCtD
Ondansetron—Syncope—Epirubicin—ovarian cancer	0.000286	0.000767	CcSEcCtD
Ondansetron—Headache—Paclitaxel—ovarian cancer	0.000286	0.000765	CcSEcCtD
Ondansetron—Hypersensitivity—Docetaxel—ovarian cancer	0.000285	0.000763	CcSEcCtD
Ondansetron—Palpitations—Epirubicin—ovarian cancer	0.000282	0.000756	CcSEcCtD
Ondansetron—Loss of consciousness—Epirubicin—ovarian cancer	0.000281	0.000752	CcSEcCtD
Ondansetron—Cough—Epirubicin—ovarian cancer	0.000279	0.000747	CcSEcCtD
Ondansetron—Vision blurred—Doxorubicin—ovarian cancer	0.000278	0.000746	CcSEcCtD
Ondansetron—Asthenia—Docetaxel—ovarian cancer	0.000277	0.000743	CcSEcCtD
Ondansetron—Convulsion—Epirubicin—ovarian cancer	0.000277	0.000741	CcSEcCtD
Ondansetron—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000274	0.000735	CcSEcCtD
Ondansetron—Pruritus—Docetaxel—ovarian cancer	0.000273	0.000733	CcSEcCtD
Ondansetron—Chest pain—Epirubicin—ovarian cancer	0.000272	0.000728	CcSEcCtD
Ondansetron—Agitation—Doxorubicin—ovarian cancer	0.000272	0.000728	CcSEcCtD
Ondansetron—Anxiety—Epirubicin—ovarian cancer	0.000271	0.000726	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.00027	0.000723	CcSEcCtD
Ondansetron—Discomfort—Epirubicin—ovarian cancer	0.000269	0.00072	CcSEcCtD
Ondansetron—Malaise—Doxorubicin—ovarian cancer	0.000266	0.000714	CcSEcCtD
Ondansetron—Dry mouth—Epirubicin—ovarian cancer	0.000266	0.000712	CcSEcCtD
Ondansetron—Syncope—Doxorubicin—ovarian cancer	0.000265	0.00071	CcSEcCtD
Ondansetron—Diarrhoea—Docetaxel—ovarian cancer	0.000264	0.000708	CcSEcCtD
Ondansetron—Palpitations—Doxorubicin—ovarian cancer	0.000261	0.0007	CcSEcCtD
Ondansetron—Anaphylactic shock—Epirubicin—ovarian cancer	0.000261	0.000698	CcSEcCtD
Ondansetron—Loss of consciousness—Doxorubicin—ovarian cancer	0.00026	0.000696	CcSEcCtD
Ondansetron—Cough—Doxorubicin—ovarian cancer	0.000258	0.000691	CcSEcCtD
Ondansetron—Shock—Epirubicin—ovarian cancer	0.000256	0.000687	CcSEcCtD
Ondansetron—Convulsion—Doxorubicin—ovarian cancer	0.000256	0.000686	CcSEcCtD
Ondansetron—Nervous system disorder—Epirubicin—ovarian cancer	0.000256	0.000685	CcSEcCtD
Ondansetron—Dizziness—Docetaxel—ovarian cancer	0.000255	0.000685	CcSEcCtD
Ondansetron—Tachycardia—Epirubicin—ovarian cancer	0.000254	0.000682	CcSEcCtD
Ondansetron—Skin disorder—Epirubicin—ovarian cancer	0.000253	0.000678	CcSEcCtD
Ondansetron—Chest pain—Doxorubicin—ovarian cancer	0.000252	0.000674	CcSEcCtD
Ondansetron—Anxiety—Doxorubicin—ovarian cancer	0.000251	0.000672	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.00025	0.000669	CcSEcCtD
Ondansetron—Discomfort—Doxorubicin—ovarian cancer	0.000249	0.000666	CcSEcCtD
Ondansetron—CYP2E1—testis—ovarian cancer	0.000246	0.0141	CbGeAlD
Ondansetron—Dry mouth—Doxorubicin—ovarian cancer	0.000246	0.000659	CcSEcCtD
Ondansetron—Vomiting—Docetaxel—ovarian cancer	0.000246	0.000658	CcSEcCtD
Ondansetron—CYP3A4—female reproductive system—ovarian cancer	0.000246	0.0141	CbGeAlD
Ondansetron—Rash—Docetaxel—ovarian cancer	0.000244	0.000653	CcSEcCtD
Ondansetron—Hypotension—Epirubicin—ovarian cancer	0.000244	0.000653	CcSEcCtD
Ondansetron—Dermatitis—Docetaxel—ovarian cancer	0.000243	0.000652	CcSEcCtD
Ondansetron—Headache—Docetaxel—ovarian cancer	0.000242	0.000649	CcSEcCtD
Ondansetron—CYP2D6—female reproductive system—ovarian cancer	0.000242	0.0139	CbGeAlD
Ondansetron—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000241	0.000646	CcSEcCtD
Ondansetron—Shock—Doxorubicin—ovarian cancer	0.000237	0.000636	CcSEcCtD
Ondansetron—Nervous system disorder—Doxorubicin—ovarian cancer	0.000236	0.000634	CcSEcCtD
Ondansetron—Tachycardia—Doxorubicin—ovarian cancer	0.000235	0.000631	CcSEcCtD
Ondansetron—Skin disorder—Doxorubicin—ovarian cancer	0.000234	0.000628	CcSEcCtD
Ondansetron—Paraesthesia—Epirubicin—ovarian cancer	0.000234	0.000627	CcSEcCtD
Ondansetron—Dyspnoea—Epirubicin—ovarian cancer	0.000232	0.000623	CcSEcCtD
Ondansetron—KCNH2—lymph node—ovarian cancer	0.000232	0.0133	CbGeAlD
Ondansetron—Somnolence—Epirubicin—ovarian cancer	0.000232	0.000621	CcSEcCtD
Ondansetron—Hypotension—Doxorubicin—ovarian cancer	0.000225	0.000604	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000225	0.000603	CcSEcCtD
Ondansetron—Fatigue—Epirubicin—ovarian cancer	0.000225	0.000602	CcSEcCtD
Ondansetron—Pain—Epirubicin—ovarian cancer	0.000223	0.000597	CcSEcCtD
Ondansetron—Constipation—Epirubicin—ovarian cancer	0.000223	0.000597	CcSEcCtD
Ondansetron—CYP2D6—female gonad—ovarian cancer	0.00022	0.0126	CbGeAlD
Ondansetron—Paraesthesia—Doxorubicin—ovarian cancer	0.000217	0.00058	CcSEcCtD
Ondansetron—Dyspnoea—Doxorubicin—ovarian cancer	0.000215	0.000576	CcSEcCtD
Ondansetron—Feeling abnormal—Epirubicin—ovarian cancer	0.000215	0.000575	CcSEcCtD
Ondansetron—Somnolence—Doxorubicin—ovarian cancer	0.000214	0.000574	CcSEcCtD
Ondansetron—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000213	0.000571	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000208	0.000558	CcSEcCtD
Ondansetron—Fatigue—Doxorubicin—ovarian cancer	0.000208	0.000557	CcSEcCtD
Ondansetron—Urticaria—Epirubicin—ovarian cancer	0.000207	0.000555	CcSEcCtD
Ondansetron—Constipation—Doxorubicin—ovarian cancer	0.000206	0.000553	CcSEcCtD
Ondansetron—Pain—Doxorubicin—ovarian cancer	0.000206	0.000553	CcSEcCtD
Ondansetron—Abdominal pain—Epirubicin—ovarian cancer	0.000206	0.000552	CcSEcCtD
Ondansetron—Body temperature increased—Epirubicin—ovarian cancer	0.000206	0.000552	CcSEcCtD
Ondansetron—Feeling abnormal—Doxorubicin—ovarian cancer	0.000199	0.000532	CcSEcCtD
Ondansetron—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000197	0.000528	CcSEcCtD
Ondansetron—CYP2D6—testis—ovarian cancer	0.000195	0.0112	CbGeAlD
Ondansetron—Hypersensitivity—Epirubicin—ovarian cancer	0.000192	0.000515	CcSEcCtD
Ondansetron—Urticaria—Doxorubicin—ovarian cancer	0.000192	0.000513	CcSEcCtD
Ondansetron—Abdominal pain—Doxorubicin—ovarian cancer	0.000191	0.000511	CcSEcCtD
Ondansetron—Body temperature increased—Doxorubicin—ovarian cancer	0.000191	0.000511	CcSEcCtD
Ondansetron—Asthenia—Epirubicin—ovarian cancer	0.000187	0.000501	CcSEcCtD
Ondansetron—Pruritus—Epirubicin—ovarian cancer	0.000184	0.000494	CcSEcCtD
Ondansetron—Diarrhoea—Epirubicin—ovarian cancer	0.000178	0.000478	CcSEcCtD
Ondansetron—Hypersensitivity—Doxorubicin—ovarian cancer	0.000178	0.000476	CcSEcCtD
Ondansetron—Asthenia—Doxorubicin—ovarian cancer	0.000173	0.000464	CcSEcCtD
Ondansetron—Dizziness—Epirubicin—ovarian cancer	0.000172	0.000462	CcSEcCtD
Ondansetron—Pruritus—Doxorubicin—ovarian cancer	0.000171	0.000457	CcSEcCtD
Ondansetron—Vomiting—Epirubicin—ovarian cancer	0.000166	0.000444	CcSEcCtD
Ondansetron—Diarrhoea—Doxorubicin—ovarian cancer	0.000165	0.000442	CcSEcCtD
Ondansetron—Rash—Epirubicin—ovarian cancer	0.000164	0.00044	CcSEcCtD
Ondansetron—Dermatitis—Epirubicin—ovarian cancer	0.000164	0.00044	CcSEcCtD
Ondansetron—Headache—Epirubicin—ovarian cancer	0.000163	0.000437	CcSEcCtD
Ondansetron—Dizziness—Doxorubicin—ovarian cancer	0.000159	0.000427	CcSEcCtD
Ondansetron—Vomiting—Doxorubicin—ovarian cancer	0.000153	0.000411	CcSEcCtD
Ondansetron—Rash—Doxorubicin—ovarian cancer	0.000152	0.000407	CcSEcCtD
Ondansetron—Dermatitis—Doxorubicin—ovarian cancer	0.000152	0.000407	CcSEcCtD
Ondansetron—Headache—Doxorubicin—ovarian cancer	0.000151	0.000405	CcSEcCtD
Ondansetron—HTR1B—Signaling by GPCR—IL2—ovarian cancer	2.23e-06	0.000416	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TERT—ovarian cancer	2.22e-06	0.000415	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYTB—ovarian cancer	2.21e-06	0.000413	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—IL2—ovarian cancer	2.17e-06	0.000405	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—SLC2A1—ovarian cancer	2.16e-06	0.000404	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—SLC2A1—ovarian cancer	2.16e-06	0.000403	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—PIK3CB—ovarian cancer	2.14e-06	0.0004	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.13e-06	0.000399	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PPP2R1A—ovarian cancer	2.13e-06	0.000398	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PIK3CD—ovarian cancer	2.12e-06	0.000396	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PIK3CA—ovarian cancer	2.09e-06	0.000391	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CYP1B1—ovarian cancer	2.07e-06	0.000387	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CYP1B1—ovarian cancer	2.07e-06	0.000386	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CXCL8—ovarian cancer	2.06e-06	0.000385	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CAV1—ovarian cancer	2.06e-06	0.000384	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—PIK3CB—ovarian cancer	2.04e-06	0.00038	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TP53—ovarian cancer	2.02e-06	0.000378	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—YAP1—ovarian cancer	1.98e-06	0.00037	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ESR1—ovarian cancer	1.98e-06	0.00037	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL2—ovarian cancer	1.97e-06	0.000368	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—YAP1—ovarian cancer	1.96e-06	0.000367	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TERT—ovarian cancer	1.96e-06	0.000366	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CXCL8—ovarian cancer	1.96e-06	0.000366	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL6ST—ovarian cancer	1.95e-06	0.000364	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.94e-06	0.000363	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—HRAS—ovarian cancer	1.94e-06	0.000362	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.93e-06	0.000361	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.93e-06	0.000361	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—APC—ovarian cancer	1.87e-06	0.00035	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CG—ovarian cancer	1.87e-06	0.00035	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—NRAS—ovarian cancer	1.87e-06	0.00035	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—IL2—ovarian cancer	1.87e-06	0.000349	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CAV1—ovarian cancer	1.87e-06	0.000348	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—IL6—ovarian cancer	1.85e-06	0.000346	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PIK3CB—ovarian cancer	1.85e-06	0.000345	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PPP2R1A—ovarian cancer	1.84e-06	0.000343	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	1.84e-06	0.000343	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.82e-06	0.000341	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CAV1—ovarian cancer	1.81e-06	0.000339	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—MAPK3—ovarian cancer	1.79e-06	0.000335	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CXCL8—ovarian cancer	1.78e-06	0.000332	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ESR1—ovarian cancer	1.75e-06	0.000326	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL6ST—ovarian cancer	1.72e-06	0.000321	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—AKT1—ovarian cancer	1.71e-06	0.000319	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.71e-06	0.000319	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ABCB1—ovarian cancer	1.71e-06	0.000319	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—MAPK1—ovarian cancer	1.71e-06	0.000319	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—EGFR—ovarian cancer	1.71e-06	0.000318	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ABCB1—ovarian cancer	1.7e-06	0.000318	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CG—ovarian cancer	1.7e-06	0.000317	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL2—ovarian cancer	1.7e-06	0.000317	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TERT—ovarian cancer	1.69e-06	0.000316	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—YAP1—ovarian cancer	1.68e-06	0.000314	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—TYMS—ovarian cancer	1.68e-06	0.000313	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—TYMS—ovarian cancer	1.67e-06	0.000313	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.66e-06	0.00031	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—APC—ovarian cancer	1.65e-06	0.000309	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CG—ovarian cancer	1.65e-06	0.000309	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—NRAS—ovarian cancer	1.65e-06	0.000309	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CD—ovarian cancer	1.65e-06	0.000307	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—PIK3CA—ovarian cancer	1.63e-06	0.000304	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—FASN—ovarian cancer	1.62e-06	0.000302	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—KRAS—ovarian cancer	1.61e-06	0.000301	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—FASN—ovarian cancer	1.6e-06	0.000299	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SLC5A5—ovarian cancer	1.59e-06	0.000297	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—MAPK3—ovarian cancer	1.58e-06	0.000295	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SLC5A5—ovarian cancer	1.58e-06	0.000294	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CAV1—ovarian cancer	1.57e-06	0.000292	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SLC2A1—ovarian cancer	1.53e-06	0.000287	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SLC2A1—ovarian cancer	1.52e-06	0.000284	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ESR1—ovarian cancer	1.51e-06	0.000282	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—MAPK1—ovarian cancer	1.51e-06	0.000281	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—EGFR—ovarian cancer	1.51e-06	0.000281	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CD—ovarian cancer	1.49e-06	0.000279	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.49e-06	0.000278	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL6ST—ovarian cancer	1.48e-06	0.000277	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—PIK3CA—ovarian cancer	1.48e-06	0.000276	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.47e-06	0.000275	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.46e-06	0.000273	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP1B1—ovarian cancer	1.46e-06	0.000272	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ERBB2—ovarian cancer	1.45e-06	0.000271	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CD—ovarian cancer	1.45e-06	0.000271	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—PIK3CA—ovarian cancer	1.44e-06	0.000269	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CB—ovarian cancer	1.43e-06	0.000268	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MTOR—ovarian cancer	1.43e-06	0.000268	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—APC—ovarian cancer	1.43e-06	0.000266	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CG—ovarian cancer	1.43e-06	0.000266	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—NRAS—ovarian cancer	1.43e-06	0.000266	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—KRAS—ovarian cancer	1.42e-06	0.000266	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CXCL8—ovarian cancer	1.38e-06	0.000257	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—HRAS—ovarian cancer	1.37e-06	0.000256	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—FASN—ovarian cancer	1.37e-06	0.000256	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—MAPK3—ovarian cancer	1.37e-06	0.000255	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CAV1—ovarian cancer	1.35e-06	0.000252	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CAV1—ovarian cancer	1.35e-06	0.000252	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SLC5A5—ovarian cancer	1.35e-06	0.000251	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CDKN1B—ovarian cancer	1.35e-06	0.000251	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—AKT1—ovarian cancer	1.33e-06	0.000249	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CASP3—ovarian cancer	1.32e-06	0.000246	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL2—ovarian cancer	1.32e-06	0.000246	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—IL6—ovarian cancer	1.31e-06	0.000245	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—PIK3CA—ovarian cancer	1.31e-06	0.000244	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	1.3e-06	0.000244	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CB—ovarian cancer	1.3e-06	0.000243	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SLC2A1—ovarian cancer	1.3e-06	0.000243	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—MAPK1—ovarian cancer	1.3e-06	0.000243	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—EGFR—ovarian cancer	1.3e-06	0.000243	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—YAP1—ovarian cancer	1.3e-06	0.000242	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	1.29e-06	0.000242	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.29e-06	0.00024	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCND1—ovarian cancer	1.28e-06	0.00024	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ERBB2—ovarian cancer	1.28e-06	0.00024	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.27e-06	0.000238	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CTNNB1—ovarian cancer	1.27e-06	0.000237	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MTOR—ovarian cancer	1.27e-06	0.000236	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CB—ovarian cancer	1.27e-06	0.000236	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CD—ovarian cancer	1.25e-06	0.000234	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MMP9—ovarian cancer	1.25e-06	0.000233	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP1B1—ovarian cancer	1.25e-06	0.000233	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—PIK3CA—ovarian cancer	1.24e-06	0.000232	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PTEN—ovarian cancer	1.24e-06	0.000231	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CG—ovarian cancer	1.23e-06	0.00023	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CG—ovarian cancer	1.23e-06	0.000229	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—KRAS—ovarian cancer	1.23e-06	0.000229	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CXCL8—ovarian cancer	1.22e-06	0.000227	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ABCB1—ovarian cancer	1.21e-06	0.000226	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—AKT1—ovarian cancer	1.21e-06	0.000226	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HRAS—ovarian cancer	1.21e-06	0.000226	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ABCB1—ovarian cancer	1.2e-06	0.000224	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—TYMS—ovarian cancer	1.19e-06	0.000222	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CDKN1B—ovarian cancer	1.19e-06	0.000222	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—TYMS—ovarian cancer	1.18e-06	0.00022	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—AKT1—ovarian cancer	1.18e-06	0.000219	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CASP3—ovarian cancer	1.16e-06	0.000217	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL2—ovarian cancer	1.16e-06	0.000217	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL6—ovarian cancer	1.16e-06	0.000216	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCND1—ovarian cancer	1.13e-06	0.000212	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PIK3CA—ovarian cancer	1.13e-06	0.000211	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTEN—ovarian cancer	1.13e-06	0.00021	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CTNNB1—ovarian cancer	1.12e-06	0.00021	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VEGFA—ovarian cancer	1.12e-06	0.000209	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—STAT3—ovarian cancer	1.11e-06	0.000207	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ERBB2—ovarian cancer	1.11e-06	0.000207	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NRAS—ovarian cancer	1.11e-06	0.000207	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	1.11e-06	0.000206	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MMP9—ovarian cancer	1.1e-06	0.000205	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.1e-06	0.000205	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PTEN—ovarian cancer	1.09e-06	0.000204	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MTOR—ovarian cancer	1.09e-06	0.000204	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CB—ovarian cancer	1.09e-06	0.000204	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CD—ovarian cancer	1.08e-06	0.000202	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CD—ovarian cancer	1.08e-06	0.000202	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—AKT1—ovarian cancer	1.07e-06	0.000199	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MAPK3—ovarian cancer	1.06e-06	0.000198	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—FASN—ovarian cancer	1.06e-06	0.000197	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CXCL8—ovarian cancer	1.05e-06	0.000196	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HRAS—ovarian cancer	1.04e-06	0.000195	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.04e-06	0.000194	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MYC—ovarian cancer	1.03e-06	0.000192	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ABCB1—ovarian cancer	1.03e-06	0.000192	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CDKN1B—ovarian cancer	1.03e-06	0.000191	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—AKT1—ovarian cancer	1.01e-06	0.000189	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—TYMS—ovarian cancer	1.01e-06	0.000188	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MAPK1—ovarian cancer	1.01e-06	0.000188	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EGFR—ovarian cancer	1.01e-06	0.000188	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CASP3—ovarian cancer	1.01e-06	0.000188	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL2—ovarian cancer	1e-06	0.000187	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1e-06	0.000187	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL6—ovarian cancer	9.99e-07	0.000186	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VEGFA—ovarian cancer	9.88e-07	0.000185	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—STAT3—ovarian cancer	9.78e-07	0.000183	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCND1—ovarian cancer	9.78e-07	0.000183	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NRAS—ovarian cancer	9.76e-07	0.000182	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CTNNB1—ovarian cancer	9.69e-07	0.000181	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP1B1—ovarian cancer	9.62e-07	0.00018	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CAV1—ovarian cancer	9.59e-07	0.000179	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KRAS—ovarian cancer	9.52e-07	0.000178	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CAV1—ovarian cancer	9.51e-07	0.000178	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MMP9—ovarian cancer	9.5e-07	0.000177	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PTEN—ovarian cancer	9.44e-07	0.000176	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CB—ovarian cancer	9.43e-07	0.000176	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CB—ovarian cancer	9.41e-07	0.000176	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK3—ovarian cancer	9.35e-07	0.000175	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—AKT1—ovarian cancer	9.21e-07	0.000172	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MYC—ovarian cancer	9.09e-07	0.00017	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	9.08e-07	0.00017	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MAPK1—ovarian cancer	8.89e-07	0.000166	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EGFR—ovarian cancer	8.89e-07	0.000166	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CA—ovarian cancer	8.74e-07	0.000163	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CG—ovarian cancer	8.73e-07	0.000163	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CG—ovarian cancer	8.66e-07	0.000162	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	8.53e-07	0.000159	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	8.53e-07	0.000159	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—ovarian cancer	8.46e-07	0.000158	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—STAT3—ovarian cancer	8.44e-07	0.000158	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NRAS—ovarian cancer	8.42e-07	0.000157	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KRAS—ovarian cancer	8.4e-07	0.000157	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTEN—ovarian cancer	8.15e-07	0.000152	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTEN—ovarian cancer	8.13e-07	0.000152	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CAV1—ovarian cancer	8.12e-07	0.000152	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HRAS—ovarian cancer	8.09e-07	0.000151	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	8.07e-07	0.000151	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CA—ovarian cancer	7.94e-07	0.000148	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ABCB1—ovarian cancer	7.92e-07	0.000148	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MYC—ovarian cancer	7.85e-07	0.000147	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—TYMS—ovarian cancer	7.78e-07	0.000145	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.76e-07	0.000145	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL6—ovarian cancer	7.74e-07	0.000145	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CA—ovarian cancer	7.72e-07	0.000144	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CD—ovarian cancer	7.68e-07	0.000143	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	7.68e-07	0.000143	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EGFR—ovarian cancer	7.68e-07	0.000143	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CD—ovarian cancer	7.61e-07	0.000142	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—ovarian cancer	7.47e-07	0.000139	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CG—ovarian cancer	7.4e-07	0.000138	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KRAS—ovarian cancer	7.25e-07	0.000135	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AKT1—ovarian cancer	7.14e-07	0.000133	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HRAS—ovarian cancer	7.14e-07	0.000133	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL6—ovarian cancer	6.83e-07	0.000128	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CB—ovarian cancer	6.69e-07	0.000125	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	6.66e-07	0.000124	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CB—ovarian cancer	6.63e-07	0.000124	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CD—ovarian cancer	6.5e-07	0.000121	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—AKT1—ovarian cancer	6.48e-07	0.000121	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—ovarian cancer	6.44e-07	0.00012	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKT1—ovarian cancer	6.3e-07	0.000118	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CAV1—ovarian cancer	6.27e-07	0.000117	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HRAS—ovarian cancer	6.16e-07	0.000115	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL6—ovarian cancer	5.9e-07	0.00011	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTEN—ovarian cancer	5.78e-07	0.000108	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CA—ovarian cancer	5.75e-07	0.000107	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CA—ovarian cancer	5.74e-07	0.000107	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTEN—ovarian cancer	5.73e-07	0.000107	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CG—ovarian cancer	5.71e-07	0.000107	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CB—ovarian cancer	5.67e-07	0.000106	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKT1—ovarian cancer	5.44e-07	0.000102	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CD—ovarian cancer	5.02e-07	9.37e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTEN—ovarian cancer	4.9e-07	9.15e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AKT1—ovarian cancer	4.7e-07	8.77e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AKT1—ovarian cancer	4.69e-07	8.75e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CB—ovarian cancer	4.38e-07	8.17e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CA—ovarian cancer	4.08e-07	7.62e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CA—ovarian cancer	4.04e-07	7.55e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTEN—ovarian cancer	3.78e-07	7.06e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CA—ovarian cancer	3.46e-07	6.45e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AKT1—ovarian cancer	3.33e-07	6.22e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AKT1—ovarian cancer	3.3e-07	6.17e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AKT1—ovarian cancer	2.82e-07	5.27e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CA—ovarian cancer	2.67e-07	4.98e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AKT1—ovarian cancer	2.18e-07	4.07e-05	CbGpPWpGaD
